Select Page

Micha Abeles M.D.

Learn More


As a result of his exceptional work in the U.S. Army, Micha Abeles M.D. decided to pursue rheumatology with a fellowship in 1976. Soon after, he was appointed to the medical staff in the division of rheumatology. In his first years on the staff, he was supported through a federal grant. He then became the Associate Director of the University of Connecticut Multipurpose Arthritis Center, which is a federally funded grant that also paid part of his salary.

Throughout the 1980s and up to 2016, Micha Abeles M.D. conducted numerous important pharmaceutical-sponsored trials that brought him great success in the workplace. Ultimately, these trials helped launch numerous new medications that lead to major improvements in the ability to treat rheumatic diseases. Examples of medications that were studied include popular names such as Enbrel, Remicade and Humira. During this time, Micha was also able to do original research which lead him to being a co-author of a fibromyalgia criteria paper published in 1990, which was the first study to fully define this syndrome.

Micha Abeles M.D. did additional studies on the subject, and he and his co-investigators eventually had 37 publications, book chapters and national presentations about fibromyalgia. In addition, Micha and his co-investigators were the first to show the association of steroid use and avascular necrosis of bone (published in 1978) and the first to show that phosphodiesterase type 5 inhibitors, which is a drug that can help smooth muscle cells that line blood vessels, could successfully treat thromboangiitis obliterans, which causes blood vessels in the hands and feet to become inflamed.

Not only was Micha Abeles M.D. well published in the fibromyalgia field, but he has several dozen publications in his name under topics such as lupus, arthritis, and osteoarthritis. If you ever get the chance to look at Micha’s extensive resume, you’ll see over a hundred publications, book chapters, papers, editorials, and letters to his name.

However, Micha Abeles’ recent work has been in the field of antibody testing with publication showing that anti-nuclear antibodies (ANA’s) were difficult to interpret and that contradictory findings in different laboratories made interpretation of their meaning even more difficult. Among other recent accomplishments, Micha Abeles M.D. was co-author of some of the first papers to describe the use of the methotrexate drug in rheumatoid arthritis and to describe eosinophilic fasciitis, which is a rare disorder where the tissue beneath the skin becomes inflamed.

Because of his extensive medical background, Micha Abeles M.D. has mentored many rheumatology fellows who now practice throughout the country. Micha has been voted as a Top Doctor in Connecticut for two decades and has been listed as Best Doctor and Castle Connolly Top Doctor for many years. He currently has a private practice in Meriden.

Telemedicine in Rheumatology

In the modern world, telemedicine is becoming more and more popular, especially among the chronically ill. Rheumatology patients can especially benefit from telemedicine due to their limited access to rheumatologists geologically and their limited mobility. While...

Maternal RA Increases Risk in Offspring

Research has shown that children born to mothers with rheumatoid arthritis (RA) could be more susceptible to certain diseases, including RA itself.

Yes, It’s Possible for Democrats AND Republicans to Constructively Work Together to Fix Healthcare

If Congress can work together then they may be able to restabilize the markets and help reduce price increases in 2018.

Here’s What The Same Arthritis Drug Costs In Different Countries

In the wake of the much-publicized drug price hikes of common prescriptions such as Mylan’s Epipen and Turing’s Daraprim, patients and doctors alike have been scratching their heads about why drug prices keep increasing. Some reasons may be the rise of the cost of living, corporate greed, or just the facts of supply and demand. Regardless of the reasoning, everyone can agree that drug prices, whether they’re name brand or not, are high in the United States.

About the Annual European Congress of Rheumatology

If you’re a practicing rheumatologist who keeps up with field news by subscribing to Rheum Now and Cleveland Clinic’s Rheumatology Daily Briefing e-newsletters, then you’ve probably heard a lot about the Annual European Congress of Rheumatology recently.